[治疗策略针对 HER2 的胃癌]
1Dept. of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo.
HER2阳性胃癌治疗已经从trastuzumab演变为抗体-药物联合体 (ADCs). 将抗HER2药物与免疫检查点抑制剂结合起来,对未来的策略有很大的希望.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- HER2阳性胃癌影响30%-40%的患者.
- 自ToGA试验以来,Trastuzumab一直是标准的第一线治疗.
- 新的治疗方法,如抗体药物联合体 (ADCs) 正在出现.
研究的目的:
- 审查 HER2 阳性胃癌的主要临床试验.
- 讨论涉及抗HER2药物和免疫检查点抑制剂的治疗策略.
- 探索这个领域的前景和挑战.
主要方法:
- 关键临床试验的文献综述.
- 对治疗组合和序列的分析.
- 讨论新兴的治疗方法.
主要成果:
- 特拉斯图祖马布仍然是基石,但ADCs提供了新的选择.
- 抗HER2剂和免疫检查点抑制剂的组合显示出潜在的.
- 目前正在进行的研究正在完善治疗模式.
结论:
- 对HER2阳性胃癌的治疗领域正在迅速发展.
- 治疗的战略序列和组合是至关重要的.
- 需要进一步的研究来优化结果和克服挑战.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Mitogens and the Cell Cycle
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
